1. Home
  2. Stock quotes
  3. Neogen Corporation
  4. Financial Statements
  5. Income Statement
Neogen Corporation logo
Neogen Corporation NEOG
$ 10.34 3.61%

Quarterly report 2025-Q4
added 01-08-2026

report update icon

Neogen Corporation Income Statement 2011-2026 | NEOG

Annual Income Statement Neogen Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 1.02 B 3.81 B 4.5 B 2.45 B 3.88 B 4.2 B 3.24 B 4.15 B 2.64 B 2.11 B 1.76 B 1.49 B 1.34 B 1.09 B 1.04 B

Shares

 217 M 216 M 189 M 108 M 106 M 105 M 104 M 103 M 102 M 100 M 99 M 98 M 96.2 M 94.5 M 92 M

Historical Prices

 4.7 17.6 23.8 22.8 36.5 40.4 33.6 30.5 29.5 24.8 19.6 17.3 15.8 11.6 8.14

Net Income

 -1.09 B -9.42 M -22.9 M 48.3 M 60.9 M 59.5 M 60.2 M 63.1 M 43.8 M 36.6 M 33.5 M 28.2 M 27.2 M 22.5 M 22.8 M

Revenue

 895 M 924 M 822 M 527 M 468 M 418 M 414 M 402 M 362 M 321 M 283 M 247 M 208 M 184 M 173 M

Cost of Revenue

 473 M 460 M 416 M 284 M 253 M 222 M 222 M 212 M 190 M 168 M 143 M 125 M 98 M 91.6 M 84.9 M

Gross Profit

 421 M 464 M 406 M 243 M 215 M 196 M 192 M 190 M 172 M 153 M 140 M 123 M 109 M 92.4 M 87.8 M

Operating Income

 -1.06 B 58.7 M 37.5 M 58.6 M 74.2 M 67.5 M 68.1 M 70.2 M 64.9 M 56.4 M 53.1 M 43.4 M 40.7 M 33.7 M 35.8 M

Interest Expense

 38.1 M 42.2 M -6.76 M 322 K -515 K -1.21 M 32 K 1.08 M 719 K -1.41 M -1.12 M -744 K -59 K -490 K -265 K

EBITDA

 -942 M 175 M 126 M 82.3 M 95.2 M 85.9 M 85.7 M 87.3 M 79.6 M 68.9 M 63.8 M 52.6 M 48.1 M 39.9 M 41.2 M

Operating Expenses

 1.48 B 405 M 368 M 184 M 141 M 129 M 124 M 120 M 107 M 96.7 M 86.6 M 79.2 M 68.8 M 58.7 M 52 M

General and Administrative Expenses

 218 M 200 M 201 M 82.7 M 51.2 M 44.3 M 40.8 M 38.3 M 34.2 M 29.2 M 25.2 M 24.4 M 20.2 M 17 M 15.1 M

All numbers in USD currency

Quarterly Income Statement Neogen Corporation

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 217 M 217 M 217 M 217 M 217 M 217 M 217 M 217 M 216 M 216 M 216 M 216 M 216 M 108 M 108 M 108 M 108 M 107 M 108 M 107 M 106 M 106 M 53.1 M 52.8 M 52.6 M 52.3 M 52.6 M 52.3 M 52 M 51.8 M 52 M 51.8 M 51.3 M 50.9 M 51.3 M 38.2 M 50.4 M 37.6 M 37.8 M 37.6 M 37.4 M 37.2 M 37.4 M 37 M 36.9 M 36.8 M 36.9 M 36.8 M 36.5 M 36.2 M 36.5 M 24.1 M 35.7 M 23.7 M 23.8 M 23.7 M 23.4 M 23.3 M 23.4 M 23.3 M

Net Income

 -15.9 M 36.3 M - -11 M -456 M -12.6 M - -2.02 M -3.49 M 1.5 M - 8.19 M -41.8 M 5.21 M -36.6 M 5.44 M 10.8 M 17.1 M 27.9 M 13.4 M 15.9 M 15.9 M 15.9 M 12.2 M 16.3 M 14.7 M 16.3 M 14.7 M 16.1 M 15.2 M 16.1 M 15.2 M 17.1 M 11.9 M 17.1 M 11.9 M 11.2 M 9.88 M 11.2 M 9.88 M 9.14 M 9.29 M 9.07 M 9.32 M 7.83 M 8.91 M 7.81 M 8.88 M 6.21 M 7.84 M 6.21 M 7.84 M 6.79 M 6.71 M 6.79 M 6.71 M 5.24 M 6 M 5.24 M 6 M

Revenue

 225 M 209 M - 221 M 231 M 217 M - 229 M 230 M 229 M - 218 M 230 M 132 M 362 M 128 M 131 M 128 M 259 M 117 M 115 M 109 M 115 M 99.9 M 108 M 101 M 108 M 101 M 107 M 99.6 M 107 M 95.9 M 102 M 95.3 M 197 M 88.4 M 90.7 M 83.6 M 90.7 M 83.6 M 79.6 M 74.9 M 79.6 M 74.9 M 68.5 M 67.6 M 68.5 M 67.6 M 59.6 M 58.5 M 59.6 M 58.5 M 50.7 M 49.7 M 50.7 M 49.7 M 44.9 M 45.7 M 44.9 M 45.7 M

Cost of Revenue

 118 M 114 M - 111 M 118 M 112 M - 112 M 113 M 112 M - 110 M 117 M 70.1 M 188 M 70.8 M 69.9 M 68.3 M 138 M 62.9 M 61.8 M 59 M 61.8 M 54.5 M 56.8 M 53.2 M 56.8 M 53.2 M 57.1 M 52.9 M 57.1 M 50.4 M 52.5 M 49.4 M 102 M 47.5 M 47.1 M 43.2 M 47.1 M 43.2 M 41.4 M 37.1 M 41.4 M 34.7 M 34.2 M 33.5 M 34.2 M 33.5 M 30.1 M 28.2 M 30.1 M 28.2 M 23.4 M 23.2 M - - - - - -

Gross Profit

 107 M 95 M - 110 M 113 M 105 M - 117 M 117 M 117 M - 108 M 113 M 62.3 M 175 M 57.4 M 60.6 M 60 M 121 M 53.8 M 53.2 M 50.3 M 53.2 M 45.3 M 51 M 48.2 M 51 M 48.2 M 50 M 46.7 M 50 M 46.7 M 48.2 M 44.9 M 49.3 M 45.9 M 43.6 M 40.5 M 43.6 M 40.5 M 38.2 M 37.8 M 38.2 M 37.8 M 34.2 M 34.1 M 34.2 M 34.1 M 29.5 M 30.4 M 29.5 M 30.4 M 27.3 M 26.5 M 27.3 M 26.5 M 22.7 M 23 M 22.7 M 23 M

Operating Income

 -5.38 M -16.1 M - 5.42 M -457 M 2.26 M - 12 M 14.5 M 19.1 M - 15.7 M -7.66 M 6.06 M -1.59 M 6.38 M 12.5 M 21.7 M 34.2 M 15.8 M 19.2 M 18.9 M 19.2 M 13 M 18.3 M 16.3 M 18.3 M 16.3 M 18.2 M 16.5 M 18.2 M 16.5 M 18 M 16.4 M 18 M 16.4 M 16.9 M 14.7 M 16.9 M 14.7 M 14.6 M 14.9 M 14.6 M 12.2 M 12.9 M 13.4 M 12.9 M 13.4 M 9.69 M 12.4 M 9.69 M 12.4 M 10.5 M 10.3 M 10.5 M 10.3 M 8.14 M 9.35 M 8.14 M 9.35 M

Interest Expense

 -731 K -967 K - 1.9 M -1.72 M -244 K - -1.17 M -2.04 M -806 K - 9.06 M 8.33 M -372 K 8.5 M -48 K 235 K -221 K 14 K -91 K -465 K 193 K -465 K -393 K -317 K -122 K -317 K -122 K 427 K -269 K 427 K -269 K 626 K 443 K 626 K 443 K -377 K 369 K -377 K 369 K -471 K -524 K -471 K -508 K -64 K -16 K -64 K -16 K 11 K -552 K 11 K -552 K 75 K 47 K 75 K 47 K -40 K -33 K -32 K -68 K

EBITDA

 - 13 M - - - 32.1 M - 35.7 M 38.2 M 47.9 M - 38.6 M 15 M 11.8 M 30.9 M 8.98 M 14.9 M 27.4 M 45.7 M 15.8 M 19.2 M 23.6 M 28.8 M 13 M 18.3 M 20.7 M 27.3 M 20.7 M 18.2 M 20.8 M 26.8 M 20.8 M 18 M 20.4 M 26.3 M 20.4 M 16.9 M 18.2 M 23.9 M 18.2 M 14.6 M 17.6 M 20.3 M 12.2 M 12.9 M 16 M 18.1 M 16 M 9.69 M 14.4 M 13.9 M 14.4 M 10.5 M 12 M 13.8 M 12 M 8.14 M 10.7 M 11.1 M 10.7 M

Operating Expenses

 112 M 111 M - 105 M 571 M 103 M - 105 M 102 M 97.6 M - 92.3 M 120 M 56.2 M 176 M 51 M 48.1 M 38.3 M 86.4 M 38.1 M 34 M 31.4 M 34 M 32.3 M 32.8 M 31.9 M 32.8 M 31.9 M 31.8 M 30.2 M 31.8 M 30.2 M 30.2 M 28.5 M 31.3 M 29.4 M 26.7 M 25.7 M 26.7 M 25.7 M 23.6 M 22.9 M 23.6 M 21.5 M 21.3 M 20.6 M 21.3 M 20.6 M 19.8 M 17.9 M 19.8 M 17.9 M 16.8 M 16.2 M 16.8 M 16.2 M 14.5 M 13.6 M 14.5 M 13.6 M

General and Administrative Expenses

 65.2 M 60.9 M - 55.8 M 57.8 M 51.7 M - 52.1 M 51.7 M 45.1 M - 46.4 M 77 M 27.9 M 105 M 25 M 22.6 M 13.4 M 36 M 15.1 M 12.2 M 11 M 12.2 M 10.8 M 11 M 10.7 M 11 M 10.7 M 10.1 M 10.2 M 10.1 M 10.2 M 10.5 M 9.32 M 10.5 M 9.32 M 8.28 M 8.26 M 8.28 M 8.26 M 6.79 M 6.75 M 6.79 M 6.52 M 6.09 M 6.01 M 6.09 M 6.01 M 6.28 M 5.54 M 6.28 M 5.54 M 4.9 M 4.48 M 4.9 M 4.48 M 4.17 M 4.01 M 4.17 M 4.01 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Neogen Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
 		- -6.23 % $ 30.6 M germanyGermany
Agilent Technologies Agilent Technologies
A
 		$ 116.92 2.67 % $ 35.5 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
 		- -6.19 % $ 10.5 M usaUSA
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
 		$ 1.18 0.85 % $ 6.43 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
 		$ 17.92 1.41 % $ 955 M usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
 		- - $ 19.8 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
 		- - $ 562 M britainBritain
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
 		$ 16.24 0.93 % $ 175 M chinaChina
Co-Diagnostics Co-Diagnostics
CODX
 		$ 4.4 101.83 % $ 5.85 M usaUSA
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
 		$ 1.98 -0.63 % $ 8.76 M usaUSA
Illumina Illumina
ILMN
 		$ 128.0 1.23 % $ 20.4 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
 		$ 25.19 1.45 % $ 700 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
 		- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
 		- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
 		- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
 		- 0.12 % $ 80.1 M chinaChina
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
 		$ 274.72 2.06 % $ 22.9 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
 		$ 175.07 3.26 % $ 8.68 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
 		- - $ 10.7 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
 		$ 520.65 2.39 % $ 15 B usaUSA
Danaher Corporation Danaher Corporation
DHR
 		$ 196.19 2.71 % $ 140 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
Myriad Genetics Myriad Genetics
MYGN
 		$ 4.77 0.63 % $ 442 M usaUSA
National Research Corporation National Research Corporation
NRC
 		$ 17.26 1.29 % $ 386 M usaUSA
Natera Natera
NTRA
 		$ 210.83 0.75 % $ 20.7 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
 		- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
 		- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
 		- -16.95 % $ 1.54 M usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
 		$ 15.83 -0.5 % $ 479 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
 		$ 1.47 2.08 % $ 441 M usaUSA
Guardant Health Guardant Health
GH
 		$ 92.84 -0.49 % $ 11.6 B usaUSA
PerkinElmer PerkinElmer
PKI
 		- -0.91 % $ 14.7 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
 		- - $ 10.6 B niderlandNiderland
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
Personalis Personalis
PSNL
 		$ 6.33 2.59 % $ 375 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
 		$ 2.73 1.49 % $ 88.6 K usaUSA
Biomerica Biomerica
BMRA
 		$ 2.15 -0.46 % $ 4.94 M usaUSA
Quotient Limited Quotient Limited
QTNT
 		- -11.32 % $ 1.1 M schweizSchweiz
ICON Public Limited Company ICON Public Limited Company
ICLR
 		$ 106.54 -0.58 % $ 8.79 B irlandaIrlanda
Check-Cap Ltd. Check-Cap Ltd.
CHEK
 		- - $ 9.42 M israelIsrael
Celcuity Celcuity
CELC
 		$ 116.94 1.19 % $ 5.47 B usaUSA